Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Autor: Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E

Publikováno v: NATURE MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c974884704314d390703b8a31e142e0d
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13819

PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES

Autor: Follo, My, Malagola, Michele, Filì, C, Finelli, C, Iacobucci, I, Martinelli, G, Cattina, F, Clissa, C, Candoni, A, Fanin, R, Gobbi, M, Bocchia, M, Defina, M, Spedini, P, Skert, C, Manzoli, L, Cocco, L, Russo, Domenico

Hypomethylating agents, such as 5-Azacytidine (AZA), significantly modified the therapeutic approach to MDS, primarily in older patients with higher risk disease for whom intensive chemotherapy and allogeneic stem cell transplantation are not an opti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::91f550eda974c4b0b22a4acb5b6c01d6
http://hdl.handle.net/11585/396790

CLINICAL RESPONSE TO THE ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. A RANDOMIZED PHASE II MULTICENTER STUDY

Autor: Finelli, C, Clissa, C, Follo, My, Stanzani, M, Parisi, S, Avanzini, P, Bosi, C, Castagnari, B, Candoni, A, Crugnola, M, Giannini, Mb, Gobbi, M, Leonardi, G, Rigolin, Gian Matteo, Russo, D, Tosi, P, Visani, G, Cocco, L, Cavo, M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3709::04aa6eefe152ea261fe7a5830cc5e348
http://hdl.handle.net/11392/2363408

Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients

Autor: Finelli, C, Clissa, C, Voso, Mt, Spiriti, Maa, Breccia, M, Gaidano, G, Crugnola, M, Giannini, Mb, Poloni, A, Bosi, C, Naso, V, Follo, My, Martinelli, G, Cavo, M

Background: Although azacitidine (AZA) has proven effective in myelodysplastic syndromes (MDS), the duration of haematologic response is limited. Introduction: The French Group (Itzykson 2011) identified some clinical and haematologic parameters (poo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::232fd32bddd54e1fa952b2d35d703ae8
http://hdl.handle.net/11585/396003

Clinical and biological effects of 5-azacytidine five days/monthly in symptomatic low-risk (IPSS: 0-1) myelodisplastic patients

Autor: Filì, C, Bergonzi, C, Skert, C, Malagola, Michele, Roccaro, Am, Peli, A, Turra, A, Colombi, C, Martinelli, G, Finelli, C, Clissa, C, Iacobucci, I, Ottaviani, E, Cocco, L, Follo, My, Candoni, A, Simeone, E, Gobbi, M, Miglino, M, Russo, Domenico

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3662::967f8ae9664450e80563f0c3d29ce040
http://hdl.handle.net/11379/31247